A case of learning difficulties, dysmorphic features, Type 2 diabetes, ulcerative colitis and suspected Albright osteodystrophy

2017 ◽  
Author(s):  
Suzanne Elkholy ◽  
Tara Montgomery
Keyword(s):  
Type 2 Diabetes ◽  
Ulcerative Colitis ◽  
Learning Difficulties ◽  
Dysmorphic Features

scholarly journals Curcumin in Autoimmune and Rheumatic Diseases

Nutrients ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 1004 ◽  
Author(s):  
Melissa Yang ◽  
Umair Akbar ◽  
Chandra Mohan
Keyword(s):  
Type 2 Diabetes ◽  
Ulcerative Colitis ◽  
Clinical Trials ◽  
Therapeutic Agent ◽  
Standard Of Care ◽  
Cohort Size ◽  
Lipid Levels ◽  
Current Standard

Over recent decades, many clinical trials on curcumin supplementation have been conducted on various autoimmune diseases including osteoarthritis, type 2 diabetes, and ulcerative colitis patients. This review attempts to summarize the highlights from these clinical trials. The efficacy of curcumin either alone or in conjunction with existing treatment was evaluated. Sixteen clinical trials have been conducted in osteoarthritis, 14 of which yielded significant improvements in multiple disease parameters. Eight trials have been conducted in type 2 diabetes, all yielding significant improvement in clinical or laboratory outcomes. Three trials were in ulcerative colitis, two of which yielded significant improvement in at least one clinical outcome. Additionally, two clinical trials on rheumatoid arthritis, one clinical trial on lupus nephritis, and two clinical trials on multiple sclerosis resulted in inconclusive results. Longer duration, larger cohort size, and multiple dosage arm trials are warranted to establish the long term benefits of curcumin supplementation. Multiple mechanisms of action of curcumin on these diseases have been researched, including the modulation of the eicosanoid pathway towards a more anti-inflammatory pathway, and the modulation of serum lipid levels towards a favorable profile. Overall, curcumin supplementation emerges as an effective therapeutic agent with minimal-to-no side effects, which can be added in conjunction to current standard of care.

scholarly journals MON-LB018 Paediatric Type 2 Diabetes in a Single Centre in East London in the Period 2009-2018

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Evelien F Gevers ◽  
Anna Giuffrida
Keyword(s):  
Type 2 Diabetes ◽  
Learning Difficulties ◽  
Current Treatment ◽  
Sleep Apnoea ◽  
Temporary Reduction ◽  
Prandial Insulin ◽  
Acting Insulin ◽  
New Treatment ◽  
Long Acting

Abstract Background: The incidence of Paediatric type 2 diabetes is increasing, especially in areas of deprivation. Aim: To describe the cohort of CYP with T2D in Royal London Hospital over the period 2009-2018. Methods: Retrospective analysis of patient cohort. Results: Number of new patients doubled from 2.6/year in 2009-2013 to 5.3/year in 2014-2018. Prevalence in our cohort is 7.5% (national average of 2.5%, NPDA 2017-2018). Fourty patients (25 female, 15 male) were diagnosed in 2009-2018, with a mean age at diagnosis of 13.9+/-1.7 yrs. Males had more frequently learning difficulties compared to females (40% vs 20%). Sixty % of patients were Asian compared to 28% in our T1D cohort. BMI at presentation was 31.5 kg/m2 (23 females) and 33.85 kg/m2 (13 males). BMI remained stable for females for the first year after diagnosis but in males increased to 34.6 kg/m2 (n=10, non significant (ns)). At diagnosis, Metformin was started in 38/40 patients although 7 patients reduced the dose and 6 stopped due to side effects. 12/36 patients started also on long-acting insulin (0.28+/-0.17U/kg), in 6 combined with prandial insulin (0.42+/-0.20U/kg). Seven patients started long-acting insulin at a later stage and 6 required prandial insulin too. 1 patient was treated with Sitagliptin. HbA1c at diagnosis (n=27) was 75.2+/- 20mmol/mol, similar for males and females.HbA1c dropped to 55.0+/-17.4mmol/mol after 3 months (P<0.0001), to increase again to 63.0+/-25.8 and 67+/-28 after one (n=25, ns) and 2 years (n=23, ns). Nineteen of 38 patients achieved a HbA1c < 48 at least once, but only 9 of 35 achieved an HbA1c < 48 for a year. Of these, 3 continued to be on insulin and in 1 patient insulin was stopped. Two patients relapsed. Complications were as follows: 11/21 hypertension, 6/28 sleep apnoea, 10/30 raised ALT and 9/24 fatty liver. Conclusion: Learning difficulties in patients with T2D are frequent. Complications of obesity/T2D are common in this cohort. Current treatment does not achieve permanent reduction in BMI and HbA1c in most patients although temporary reduction of HbA1c is possible. New treatment approaches are needed to improve outcomes.

scholarly journals Bacterial Bile Metabolising Gene Abundance in Crohn's, Ulcerative Colitis and Type 2 Diabetes Metagenomes

PLoS ONE ◽  
2014 ◽  
Vol 9 (12) ◽  
pp. e115175 ◽  
Author(s):  
Alain Labbé ◽  
Jorge G. Ganopolsky ◽  
Christopher J. Martoni ◽  
Satya Prakash ◽  
Mitchell L. Jones
Keyword(s):  
Type 2 Diabetes ◽  
Ulcerative Colitis ◽  
Gene Abundance

scholarly journals Case Report on pyoderma gangrenosum associated with Ulcerative Colitis

2020 ◽  
Vol 11 (SPL4) ◽  
pp. 2900-2902
Author(s):  
Anusha Narayanan ◽  
Rama P Venu ◽  
Roshni PR
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Ulcerative Colitis ◽  
Type 2 Diabetes Mellitus ◽  
Pyoderma Gangrenosum ◽  
Pedal Oedema ◽  
Neutrophilic Dermatoses ◽  
History Of ◽  
The Right

Pyoderma gangrenosum is rare neutrophilic dermatoses that exist as inflammatory and ulcerative disorders of the skin and is neither an infectious nor gangrenous condition. It is commonly associated with an autoimmune disease like ulcerative colitis and crohn’s disease. It has an estimated incidence of 3-10 cases per million people per year. This is a case of a 28-year-old patient who was admitted with features of pyoderma gangrenosum: papule over the shin of the right leg which progressively increased in size. She had a history of ulcerative colitis and type 2 Diabetes mellitus and developed a papule in the right leg one month back which progressed to a larger ulcer and a similar lesion developing proximal to this. The lesions were painful, two lesions over the right tibial shin each measuring about 5x5cm, with erythema, pedal oedema and associated with fever and She was treated with antibiotics, steroids (hydrocortisone), cyclosporine and other supportive care. Daily dressing of the wound was done, and saline compresses were applied and was advised to continue the same after discharge. With the above measures, she improved clinically and was stable at discharge. As there is no diagnostic test for PG (since it is a diagnosis of exclusion) and if the disease is present but unrecognized, the results can be devastating. Hence timely onset of therapeutic approach is of utmost importance.

1045: Pioglitazone Ameliorates Penile Corpora Veno-Occlusive Dysfunction (CVOD) in a Rat Model of Type 2 Diabetes

2005 ◽  
Vol 173 (4S) ◽  
pp. 283-284
Author(s):  
Istvan Kovanecz ◽  
Monica G. Ferrini ◽  
Hugo H. Davila ◽  
Jacob Rajfer ◽  
Nestor F. Gonzalez-Cadavid
Keyword(s):  
Type 2 Diabetes ◽  
Rat Model
Sign in / Sign up

Export Citation Format

Share Document